Restricted accessReview articleFirst published online 2026
Pediatric pharmaceutical forms in oncology: A review of galenic challenges,difficulties encountered in hospital practice,and perspectives offered by new technologies
To review the pharmaceutical challenges associated with pediatric anticancer formulations and discuss current limitations, hospital practice difficulties, and emerging technological strategies to improve safety, accuracy, and acceptability of pediatric oncology treatments.
Data Sources
Relevant literature on pediatric oncology formulations, compounding practices, and innovative drug-delivery technologies was analyzed using a narrative review approach.
Data Summary
Pediatric oncology presents unique pharmaceutical challenges due to the limited availability of age-appropriate anticancer formulations. Because most anticancer drugs are developed for adults, pediatric treatment frequently relies on off-label use and extemporaneous manipulation of dosage forms, raising concerns regarding dose accuracy, stability, excipient-related toxicity, and occupational safety in hospital settings. Extemporaneous compounding may lead to dosing variability, reduced stability, and healthcare professional exposure to hazardous drugs. Emerging approaches, including 3D-printed individualized mini-tablets, orodispersible films, nanocarrier-based delivery systems, physiologically based pharmacokinetic modeling, and therapeutic drug monitoring, show potential to improve dosing precision, safety, and treatment acceptability.
Conclusions
The lack of suitable pediatric anticancer formulations remains a major barrier to safe and effective therapy. Hospital pharmacists play a central role in mitigating formulation-related risks through controlled preparation and innovative practices. Integration of emerging pharmaceutical technologies into clinical practice may enable safer, more standardized, and individualized pediatric oncology treatments.
JohannessonJHanssonPBergströmCAS,et al.Manipulations and age-appropriateness of oral medications in pediatric oncology patients in Sweden: need for personalized dosage forms. Biomed Pharmacother2022 Feb; 146: 112576. Epub 2021 Dec 29. PMID: 35062056.
2.
AnderssonÅCEksborgSFörbergU, et al.Frequency of paediatric patients administered extemporaneous preparations at a Swedish university hospital: a registry-based study comparing two study-years, 10 years apart. Eur J Hosp Pharm2023 Aug 8: ejhpharm-2023-003804. doi: 10.1136/ejhpharm-2023-003804. Epub ahead of print. PMID: 37553231.
3.
KasahunAESendekieAK. Are pediatrics taking the prescribed tablet dosage form? Practices of off-label tablet modification in pediatric wards: a prospective observational study. Heliyon2023 Apr 1; 9: e15109. PMID: 37077681; PMCID: PMC10106910.
4.
SuleOStaderFKassirN. Utilizing minimal physiologically based pharmacokinetic modeling to bridge bevacizumab pharmacokinetics from adult to pediatric patients. AAPS J2026; 28: 15.
5.
ZuninoCGualanoVZhouH, et al.Prediction of monoclonal antibody pharmacokinetics in pediatric populations using PBPK modeling and simulation. Pharmaceutics2025; 17: 884.
6.
UsmaniMTShoaibMHSiddiquiF. Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets. Sci Rep2023; 13: 16070.
7.
BahmanMBernhardtMBBrasherCA, et al.Advancing non-sterile pediatric pharmacotherapy through automated compounding and 3D printing of ondansetron hcl dihydrate dosage forms. J Oncol Pharm Pract2026 Jan; 32: 71–86. Epub 2025 Oct 25. PMID: 41138268; PMCID: PMC12647376.
8.
MacArthurRBAshworthLDZhanK, et al. II. How compounding pharmacies fill critical gaps in pediatric drug development processes: suggested regulatory changes to meet future challenges. Children2022; 9: 1885.
9.
YulianiSHPutriDCAVirginiaDM, et al.Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: a review. Pharmaceutics2023; 15: 40.
10.
LuisettoMAlmuktharNEdbeyK. Oral suspension as versatile galenic formulation in pediatry. Arch Pharm Pharmaceut Sci2024; 8: 091–099.
11.
CorinaBDanielLAdinaP. Acceptability of compounded preparations – A Romanian pediatric hospital perspective. Eur J Pharm Biopharm2024; 202: 114383, ISSN 0939-6411,.
12.
FaddaHMWeilerHCarvalhoM, et al.Pediatric oral extemporaneous preparations and practices: international pharmaceutical federation (FIP) global study. Eur J Pharm Biopharm2024 Nov; 204: 114483. Epub 2024 Sep 6. PMID: 39245358.
13.
JîtcăC-MJîtcăGŐszB-E, et al.Stability of oral liquid dosage forms in pediatric cardiology: a prerequisite for patient’s safety—A narrative review. Pharmaceutics2023; 15: 1306.
14.
FarooqWBaigNKhanBA, et al.Enhancement of paediatric oncology pharmacy practices in a low–middle-income country through teaching and training using the my child matters grant. J Oncol Pharm Pract2023; 30: 786–791.
15.
Van den BergHTakN. Licensing and labelling of drugs in a paediatric oncology ward. Br J Clin Pharmacol2011 Sep; 72: 474–481. PMID: 21453298; PMCID: PMC3175517.
16.
SimonNVasseurMPinturaudM. Effectiveness of a closed-system transfer device in reducing surface contamination in a new antineoplastic drug-compounding unit: a prospective, controlled, parallel study. PLoS One2016 Jul 8; 11: e0159052. PMID: 27391697; PMCID: PMC4938267.
17.
Saint-LorantGVasseurMAllorgeD, et al.Four-year follow-up of surface contamination by antineoplastic drugs in a compounding unit. Occup Environ Med2023 Mar; 80: 146–153. Epub 2023 Jan 30. PMID: 36717254.
18.
BishaySMichalowska-SuterskaMEdlingA. Evaluation of the hazardous drug surface contamination in pharmacy compounding and administration clinical setting after adoption of standardized cleaning workflow and a closed system transfer device. Pharmaceut Technol Hosp Pharm2022; 7: 20220004.
19.
NodaYKogaYYamamuraK. Cyclophosphamide exposure factors in family caregivers for pediatric cancer patients. Int J Hyg Environ Health2024; 260: 114402. ISSN 1438-4639.
20.
PowerLACoyneJW. ASHP Guidelines on handling hazardous drugs. Am J Health-Syst Pharm15 December 2018; 75: 1996–2031.
21.
LandryÉKAutmizguineJBérubéS, et al.Drug prescriptions requiring compounding at a Canadian university affiliated pediatric hospital: a cross-sectional study. Children2023; 10: 147.
22.
da SilvaMRMDysarsLPSantosEP, et al.Preparation of extemporaneous oral liquid in the hospital pharmacy. Braz J Pharm Sci2020; 56: e18358.
23.
LaverdièreJBendicho-LavillaCMahroucheL. 3D Printed hydroxyurea for pediatric use: toward personalized formulations and reduced exposure risk. Int J Pharm2025; 686: 126326. ISSN 0378-5173.
24.
LenhartJLunterDJ. Dosage by design – 3D printing individualized cabozantinib tablets with immediate release. Eur J Pharm Biopharm2024; 204: 114501. ISSN 0939-6411.
25.
BiałekAKrysztofiakJHozakowskaA. Novel soft dosage forms for paediatric applications: can we 3D-print them or not?Gels2025; 11: 87.
26.
Rodríguez-PomboLde Castro-LópezMJSánchez-PintosP. Paediatric clinical study of 3D printed personalised medicines for rare metabolic disorders. Int J Pharm2024 May 25; 657: 124140. Epub 2024 Apr 19. PMID: 38643809.
OtsokolhichMAnnereauMBautersT. SIOPE And ESOP recommendations for extemporaneous compounding of oral liquid medicine formulations in paediatric oncology. EJC Paediatr OncolJune 2024; 3: 100163.
29.
JumpeiSMikiAYoichiI. Retrospective survey of compounded medications for children in Japan. Eur J Pharm Biopharm2020; 155: 122–127. ISSN 0939-6411.
30.
SaitoJSuzukiENakamuraY. Study on the preparation method of quality-assured in-hospital drug formulation for children—A multi-institutional collaborative study. Children2023; 10: 1190.
31.
AitoJNakamuraHAkabaneM, et al.Quantitative investigation on exposure to potentially harmful excipients by injection drug administration in children under 2 years of age and analysis of association with adverse events: a single-center, retrospective observational study. Ther Innov Regul Sci2024; 58: 316–335.
32.
AbouDayaMTomlinSRashedAN. P47 extent of paediatric exposure to pharmaceutical excipients: an exploratory study. Arch Dis Child2020; 105: e31.
33.
BarbosaRSampaioCSousaL. Exposure to potentially harmful excipients in neonates admitted to intensive care units using compounded medicines. Eur J Hosp Pharm2025 Apr 15: ejhpharm-2024-004340. doi: 10.1136/ejhpharm-2024-004340. Epub ahead of print. PMID: 40234020.
34.
HassanAAl-MansouriM. Stabilization and beyond-use dating of extemporaneously compounded pediatric oral suspensions: a multicenter study. J Pharm Hosp Pharm2025; 2: 33–40.
35.
DavisCIpKBanovD,et al.Stability study of pediatric oral suspensions formulated with PCCA SuspendIt vehicle used for the treatment of cardiovascular disease. Int J Pharm Compd2025; 29: 279–290.
36.
MeyersRSThackrayJMatsonKL, et al.Key potentially inappropriate drugs in pediatrics: the KIDs list. J Pediatr Pharmacol Ther2020; 25: 175–191.
BobillotMDelannoyVTrouillardA, et al.Potentially harmful excipients: state of the art for oral liquid forms used in neonatology and pediatrics units. Pharmaceutics2024; 16: 119.
39.
Development of paediatric medicines: points to consider in formulation. Geneva, Switzerland: Wold Health Organization, 2025. Working document QAS/24.950 January 2025.
40.
BelaynehATadeseEMollaF. Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations. Int J Gen Med2020; 13: 1051–1066. Published 2020 Nov 9.
British National Formulary (BNF). London: BMJ Publishing Group and Pharmaceutical Press, 2025.
45.
LiuQChuKPCardenasA, et al.Recommendation of IV dose preparation practices using closed system transfer devices (CSTD) for accurate dosing. AAPS J2025 May 16; 27: 93. PMID: 40380038.
46.
DuboisLBouguergourCPaoli-LombardoR. Compounding and stability studies of liquid oral formulations of beta-blockers (bisoprolol, betaxolol, and nadolol) for paediatric patients. J Pharm Pharm Sci2025; 28: 15387.
47.
KousarKShafiqSSheraziST. In silico ADMET profiling of docetaxel and development of camel milk derived liposomes nanocarriers for sustained release of docetaxel in triple negative breast cancer. Sci Rep2024; 14: 912.
48.
RiouxNWatersNJ. Physiologically based pharmacokinetic modeling in pediatric oncology drug development. Drug Metab Dispos2016 Jul; 44: 934–943. Epub 2016 Mar 2. PMID: 26936973.
49.
ReisASilvaVJoaquimJJ. Health effects of ergonomics and personal protective equipment on chemotherapy professionals. Current Oncology2025; 32: 63.
50.
YanivAKnoerS. Implementation of an i.v.-compounding robot in a hospital-based cancer center pharmacy. Am J Health-Syst Pharm2013; 70: 2030–2037.
51.
VrignaudSBriotTLaunayA, et al.Design and stability study of a paediatric oral solution of methotrexate 2 mg/ml. Int J Pharm2015; 487: 270–273.
52.
Cherif ChefchaouniABoudinaYChennaqM, et al.Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology. J Oncol Pharm Pract2023; 29: 1334–1342.
53.
BennaniICherif ChefchaouniAHafidiY, et al.Advancements in the use of nanopharmaceuticals for cancer treatment. J Oncol Pharm Pract2024; 30: 1078–1083.
